Releases

Stock exchange and press releases of BBS will be published on these pages. Releases are published in Finnish and in English.

Contact information for the media: info@bbs-artebone.fi from which you can also request additional media material.

Company releases

26.11.2023
BBS-Bioactive Bone Substitutes Plc has received new subscription undertakings and supplements the Investor Memorandum dated 24th of November 2023 relating to the rights offering and publishes updated Basic Information Document

24.11.2023
BBS-Bioactive Bone Substitutes Plc publishes the Investor Memorandum and the Basic Information Document related to the Offering and information regarding Subscription undertakings

20.11.2023
CORRECTION: BBS-Bioactive Bone Substitutes Plc: BBS arranges a rights offering of approximately maximum EUR 2.63 million

20.11.2023
CORRECTION: BBS-Bioactive Bone Substitutes Plc: BBS arranges a rights offering of approximately maximum EUR 2.63 million

20.11.2023
BBS-Bioactive Bone Substitutes Plc: BBS arranges a rights offering of approximately maximum EUR 2.63 million

Press releases and Investor News

25.11.2023
BBS-Bioactive Bone Substitutes: The Notified Body has approved the Company’s quality system

24.11.2023
BBS-Bioactive Bone Substitutes Plc: New CEO Juliusz Rakowski to be interviewed by Inderes – Share issues to begin on 27 November

15.11.2023
Juliusz Rakowski starts as CEO of BBS: "My focus is already on the time after receiving the CE marking”

22.06.2023
BBS’ rights offering ongoing – The subscription period ends on 26 June in Sweden and 28 June in Finland

17.05.2023
BBS-Bioactive Bone Substitutes Plc: Fimea has conducted a regular periodic audit regarding the company's pharmaceutical factory permit

Older releases can be found from our news archive.